What makes Adc Therapeutics SA (ADCT) Stock unique?

Cantor Fitzgerald raised the price target for the Adc Therapeutics SA (NYSE:ADCT) stock to “an Overweight”. The rating was released on May 30, 2024, according to finviz. The stock was downgraded by BofA Securities, who disclosed in a research note on April 24, 2023, from Neutral to Underperform and set the price objective to $2. […]

There Is Nothing Like Adc Therapeutics SA (ADCT) Stock

Cantor Fitzgerald raised the price target for the Adc Therapeutics SA (NYSE:ADCT) stock to “an Overweight”. The rating was released on May 30, 2024, according to finviz. The stock was downgraded by BofA Securities, who disclosed in a research note on April 24, 2023, from Neutral to Underperform and set the price objective to $2. […]

The latest Adc Therapeutics SA (ADCT) Stock Technical Bulletin

Cantor Fitzgerald raised the price target for the Adc Therapeutics SA (NYSE:ADCT) stock to “an Overweight”. The rating was released on May 30, 2024, according to finviz. The stock was downgraded by BofA Securities, who disclosed in a research note on April 24, 2023, from Neutral to Underperform and set the price objective to $2. […]

Adc Therapeutics SA (ADCT) Stock Still Strong Despite Competition

Guggenheim raised the price target for the Adc Therapeutics SA (NYSE:ADCT) stock to “a Buy”. The rating was released on March 28, 2024, according to finviz. The research report from BofA Securities has downgraded the stock from Neutral to Underperform, with a price target set at $2. The stock was initiated by CapitalOne, who disclosed […]